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 What’s new with the old drug Aspirin in older adults? 
 
Andrew James Webb and Pietro Minuz 
 
The benefit-to-harm balance of aspirin has been further questioned recently. What should 
prescribers do? The European Society of Cardiology (ESC) Guidelines, most recently 
updated in 2016 [1], do not recommend the use of aspirin for primary prevention (patients 
without prior major cardio- or cerebrovascular event) due to the high risk of bleeding.  This 
position is now further supported by the results of the Aspirin in Reducing Events in the 
Elderly ASPREE trial [2]. Aspirin significantly increased the risk of major haemorrhage 
without lowering the risk of cardiovascular disease, compared to placebo.  
 
In the BJCP/Journal, Ardoino and colleagues found high rates of prescription 
of antiplatelet drugs (with aspirin being the most frequently chosen): almost half (43.6%, 
95% CI 41.5-45.7) of 959 patients aged 65 or over in Italian and Spanish internal medicine 
and geriatric wards in 2012 and 2014 (as part of the REPOSI ((REgistro POliterapie SIMI)) 
register) [3]. Moreover, just over half (52.1%) were prescribed aspirin inappropriately. In 
most cases, this was over-prescription (74.2%) in patients with a Systematic Coronary Risk 
Evaluation Project (SCORE) <10%. Against this over-prescription of aspirin for primary 
prevention, Ardoino et al., also found substantial under-prescription (30.6%) of antiplatelet 
agents in patients who were secondary prevention [3].  
 
Ardoino et al., also found further inappropriate use of antiplatelets in patients with atrial 
fibrillation (AF) - who should have been anticoagulated.  
 
The risks of major bleeding and stroke with aspirin and anticoagulants used for AF has been 
reported in the Journal by Gieling et al., who studied their use in   31,497 patients with AF 
(2008-2014) using the UK Clinical Practice Research Datalink [4]. Aspirin was found to have 
a similar bleeding risk to vitamin K antagonists (VKAs) but that VKAs were more effective 
than aspirin (hazard ratio (HR) 2.18, [95% confidence interval (95%CI) 1.83-2.59) in the 
prevention of ischaemic stroke. Whilst Nonvitamin K antagonist oral anticoagulants (NOACs) 
were similarly effective as VKA in preventing ischaemic stroke (HR 1.22, 95% CI 0.67-2.19), 
they were associated with double the risk of major bleeding – mainly gastrointestinal [2.07 
(95%CI 1.27-3.38)], a risk restricted to women (HR 3.14, 95% CI 1.76-5.60). However, 
caution should be applied as this was a retrospective cohort study, albeit in a large 
population.  
 
Despite this poor benefit-to-harm balance of aspirin, Parekh et al., found that anti-platelets 
agents were only 13th on a list of medications associated with medication-related harms 
(MRH) following hospital discharge in 1280 older adults [5]. Aspirin was behind opiates, 
antibiotics, benzodiazepines, diuretics and antihypertensives. The overall incidence of MRH-
associated hospital readmission was ~8% (78 per 1000 discharges), at an estimated cost to 
the National Health Service of £396 million annually, over 60% of which (£243 million) was 
considered to be potentially preventable [5].  
 
Therefore, whilst prescribers should remember the need for antiplatelets in secondary 
prevention, they should reconsider the use of aspirin for primary prevention and focus more 
on good control of the other risk factors: blood pressure and cholesterol (the latter mainly via 
use of statins). Perhaps the current success of these other interventions now leaves little 
room for benefit from aspirin in primary prevention?  
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